Open AccessMEK inhibitors in non-V600 BRAF mutations and fusions
Author(s) -
Douglas B. Johnson,
Caroline A. Nebhan,
Marcus Smith Noel
Publication year - 2020
Publication title -
oncotarget
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.373
H-Index - 127
ISSN - 1949-2553
DOI - 10.18632/oncotarget.27788
Subject(s) - trametinib , mek inhibitor , medicine , mutation , cancer research , genetics , biology , gene , mapk/erk pathway , kinase
Mutations in BRAF at the 600th codon have proven sensitive to combination BRAF and MEK inhibition. Mutations outside this codon, however, are approximately as common but do not have approved targeted therapy approaches. Herein, we discuss targeting these non-V600 mutation and fusions in BRAF with MEK inhibitors.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom